Article
MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Nature communications - 14 Feb 2020
Zeineldin Maged, Federico Sara, Chen Xiang, Fan Yiping, Xu Beisi, Stewart Elizabeth, Zhou Xin, Jeon Jongrye, Griffiths Lyra, Nguyen Rosa, Norrie Jackie, Easton John, Mulder Heather, Yergeau Donald, Liu Yanling, Wu Jianrong, Van Ryn Collin, Naranjo Arlene, Hogarty Michael D, Kamiński Marcin M, Valentine Marc, Pruett-Miller Shondra M, Pappo Alberto, Zhang Jinghui, Clay Michael R, Bahrami Armita, Vogel Peter, Lee Seungjae, Shelat Anang, Sarthy Jay F, Meers Michael P, George Rani E, Mardis Elaine R, Wilson Richard K, Henikoff Steven, Downing James R, Dyer Michael A
Abstract excerpt
Aggressive cancers often have activating mutations in growth-controlling oncogenes and inactivating mutations in tumor-suppressor genes. In neuroblastoma, amplification of the MYCN oncogene and inactivation of the ATRX tumor-suppressor gene correlate with high-risk disease and poor prognosis. Here we show that ATRX mutations and MYCN amplification are mutually exclusive across all ages and stages in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.